Therapeutic drug monitoring not superior to standard of care in achieving remission

Therapeutic drug monitoring, in which treatments were individually assessed and reviewed, failed to improve remission for patients with a variety of rheumatic diseases who started infliximab, according to a speaker at ACR Convergence.“The clinical utility of therapeutic drug monitoring — or TDM — for biological drugs is a current debate,” Silje Watterdal Syversen, MD, PhD, of Diakonhjemmet Hospital, in Oslo, Norway, said during a press conference at the virtual meeting. “Infliximab and TNF inhibitors have revolutionized the treatment of a number of chronicRead More

Share on facebook
Share on twitter
Share on linkedin